Safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) in homozygous MDR1-mutant collie dogs

Table 4 Summary of the mean ± SD of AVS scores after each dose cycle and all dose cycles combined

	AVS clinical signs^a	0× (control)	1×	2×	5×
First dose cycle	Depression	0.00 ± 0.00	0.00 ± 0.00	0.04 ± 0.13	0.00 ± 0.00
	Salivation/drooling/vomiting	0.01 ± 0.03	0.08 ± 0.20	0.07 ± 0.18	0.21 ± 0.27
	Overall	0.01 ± 0.03	0.08 ± 0.20	0.12 ± 0.30	0.21 ± 0.27
Second dose cycle	Depression	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.01 ± 0.03
	Salivation/drooling/vomiting	0.01 ± 0.03	0.07 ± 0.10	0.06 ± 0.13	0.21 ± 0.24
	Overall	0.01 ± 0.03	0.07 ± 0.10	0.06 ± 0.13	0.22 ± 0.24
Third dose cycle	Depression	0.02 ± 0.05	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	Salivation/drooling/vomiting	0.01 ± 0.03	0.10 ± 0.18	0.06 ± 0.10	0.24 ± 0.29
	Overall	0.03 ± 0.05	0.10 ± 0.18	0.06 ± 0.10	0.24 ± 0.29
All cycles	Depression	0.01 ± 0.02	0.00 ± 0.00	0.01 ± 0.04	0.00 ± 0.01
	Salivation/drooling/vomiting	0.01 ± 0.02	0.08 ± 0.15	0.07 ± 0.13	0.22 ± 0.25
	Overall	0.01 ± 0.02	0.08 ± 0.15	0.08 ± 0.17	0.23 ± 0.25

^aAVS clinical signs are only listed for those categories where dogs had abnormal signs. No signs were observed in any dog for seizures or convulsions, ataxia, mydriasis, or muscle tremors

ISSN: 1756-3305